Dr Charlotte Pawlyn and Dr Martin Kaiser are leading laboratory research teams and clinical trials of new treatments for myeloma, a type of blood cancer that develops in the bone marrow.
Our researchers, in partnership with The Royal Marsden and the UK Myeloma Research Alliance, have developed large-scale studies across UK hospitals that have led to the approval of new treatments such as the use of the thalidomide derivative, lenalidomide, as maintenance therapy after autologous stem cell transplant.
We discovered a new drug that could counteract drug resistance in patients with cancers including acute myeloid leukaemia.
Dr David Taussig, is leading the Phase I trial of the drug which is a dual inhibitor of cancer-driving proteins from the Aurora and FLT3 families.
Professor Richard Houlston led one of the largest population studies of blood cancers, which showed that people with a parent, sibling or child affected by blood cancer are more likely to be diagnosed with the disease. In the future, the results could help to identify people most at risk of these diseases, where genetic testing, medical observation and counselling could be beneficial.
Dr Christina Messiou was one of the first radiologists to provide a novel imaging service for patients with myeloma known as whole body diffusion weighted MRI. She is established internationally as an authority and also trains other radiologists in this approach.
Your support helps
As a UK charity, our life-saving research relies on the generosity of individuals and organisations. Our supporters help us make a difference to the lives of cancer patients and their families everywhere.